Calcifediol - Generic Drug Details

What are the generic sources for calcifediol and what is the scope of patent protection?

Calcifediol is the generic ingredient in two branded drugs marketed by Eirgen and Organon Usa Inc, and is included in two NDAs. There are sixteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Calcifediol has one hundred and eighty-six patent family members in thirty-eight countries.

There are two drug master file entries for calcifediol. One supplier is listed for this compound.

Summary for calcifediol

International Patents:	186
US Patents:	16
Tradenames:	2
Applicants:	2
NDAs:	2
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	201
Clinical Trials:	24
What excipients (inactive ingredients) are in calcifediol?	calcifediol excipients list
DailyMed Link:	calcifediol at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for calcifediol

Constraining patent/regulatory exclusivity:

9,861,644

Dosage:

CAPSULE, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for calcifediol

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hospital Universitario La Fe	PHASE4
Hospital Clinic of Barcelona	PHASE4
Universidad Complutense de Madrid	PHASE4

See all calcifediol clinical trials

Pharmacology for calcifediol

Drug Class

Vitamin D3 Analog

Medical Subject Heading (MeSH) Categories for calcifediol

Bone Density Conservation Agents

Vitamins

Anatomical Therapeutic Chemical (ATC) Classes for calcifediol

A11CC	Vitamin D and analogues
A11C	VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO
A11	VITAMINS
A	Alimentary tract and metabolism

H05BX	Other anti-parathyroid agents
H05B	ANTI-PARATHYROID AGENTS
H05	CALCIUM HOMEOSTASIS
H	Systemic hormonal preparations, excluding sex hormones and insulins

US Patents and Regulatory Information for calcifediol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes	9,861,644		Y
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes	10,213,442		Y
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes	9,943,530
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes	8,207,149
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes	8,361,488		Y

Expired US Patents for calcifediol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016	6,582,727
Organon Usa Inc	CALDEROL	calcifediol	CAPSULE;ORAL	018312-002	Approved Prior to Jan 1, 1982	3,833,622
Organon Usa Inc	CALDEROL	calcifediol	CAPSULE;ORAL	018312-002	Approved Prior to Jan 1, 1982	3,565,924
Organon Usa Inc	CALDEROL	calcifediol	CAPSULE;ORAL	018312-001	Approved Prior to Jan 1, 1982	3,565,924
Organon Usa Inc	CALDEROL	calcifediol	CAPSULE;ORAL	018312-001	Approved Prior to Jan 1, 1982	3,833,622

International Patents for calcifediol

Country	Patent Number	Title	Estimated Expiration
South Korea	101847947
Japan	2009525985
Hong Kong	1209322
Spain	2834900
Denmark	1993559

Supplementary Protection Certificates for calcifediol

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2481400	C02481400/01	Switzerland		PRODUCT NAME: CALCIFEDIOL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67614 22.12.2020
2481400	132021000000071	Italy		PRODUCT NAME: CALCIFEDIOLO(RAYALDEE); AUTHORISATION NUMBER(S) AND DATE(S): 047870011, 20201201;PL 50784/0005, 20200721
2968172	301095	Netherlands		PRODUCT NAME: CALCIFEDIOL IN IEDERE VORM ZOALS BESCHERMD DOOR HET BASISOCTROOI; NATIONAL REGISTRATION NO/DATE: 124799 20200922; FIRST REGISTRATION: DE 2202115.00.00 20200819
2968172	SPC/GB20/043	United Kingdom		PRODUCT NAME: CALCIFEDIOL, AND/OR A SALT OR HYDRATE THEREOF, IN PARTICULAR CALCIFEDIOL MONOHYDRATE; REGISTERED: UK PL 50784/0005-0001 20200721
2481400	122020000079	Germany		PRODUCT NAME: CALCIFEDIOL UND/ODER PHARMAZEUTISCH AKZEPTABLE SALZE UND HYDRATE DAVON, BEVORZUGT CALCIFEDIOLMONOHYDRAT; NAT. REGISTRATION NO/DATE: 2202115.00.00 20200818; FIRST REGISTRATION: VEREINIGTES KOENIGREICH GROSSBRITANNIEN UND NORDIRLAND PL 50784/0005 - 0001 20200721

Market Dynamics and Financial Trajectory for Calcifediol: An In-depth Analysis

Last updated: December 26, 2025

Executive Summary

Calcifediol (25-hydroxyvitamin D3) is a vital metabolite of vitamin D utilized primarily for treating vitamin D deficiency and associated disorders. Its rising prominence stems from its superior bioavailability, rapid onset of action, and emerging therapeutic applications, especially amidst the global surge in vitamin D deficiency cases. The market for calcifediol is experiencing accelerating growth driven by increasing awareness of vitamin D’s health benefits, expanding clinical applications, and evolving regulatory landscapes. This report provides a comprehensive analysis of the current market dynamics, key drivers, segment trends, competitive landscape, and financial projections, highlighting pertinent opportunities and challenges.

---

1. What are the Key Market Drivers for Calcifediol?

1.1. Rising Prevalence of Vitamin D Deficiency

• An estimated 1 billion individuals worldwide suffer from vitamin D deficiency or insufficiency, impacting populations across age groups, especially the elderly, pregnant women, and those with limited sun exposure [1].

1.2. Increasing Evidence of Therapeutic Benefits

• Research links adequate vitamin D levels to reduced risks of osteoporosis, autoimmune diseases, respiratory infections, and potential COVID-19 mitigation, prompting increased demand for supplementing agents like calcifediol [2].

1.3. Enhanced Bioavailability and Rapid Action

• Compared to cholecalciferol (vitamin D3), calcifediol demonstrates higher serum conversion efficiency, providing faster correction of deficiency, which incentivizes clinicians and patients to prefer it [3].

1.4. Strategic Regulatory Approvals and Market Penetration

• Several countries are evolving regulations to allow calcifediol-based formulations, fueling market access, especially in Europe and emerging markets [4].

1.5. Expanding Clinical Indications

• Beyond deficiency correction, calcifediol shows potential in managing secondary hyperparathyroidism, chronic kidney disease (CKD), and osteoporosis, broadening its application spectrum [5].

---

2. How is the Market for Calcifediol Segmented?

Segment Type	Sub-Segment	Details
Product Type	Pharmaceuticals	Injectables, oral solutions, capsules
	Nutritional Supplements	Over-the-counter formulations
Application Area	Deficiency Treatment	Vitamin D deficiency, malabsorption syndromes
	Chronic Disease Management	CKD, osteoporosis, autoimmune conditions
End User	Hospitals & Clinics	Prescription-based uses
	Retail Pharmacies & Online Channels	Over-the-counter supplements
Geographical Regions	North America	Leading market, dominated by U.S.
	Europe	Growing adoption, regulatory support
	Asia-Pacific	Rapid market expansion, emerging economies
	Rest of the World	Increasing awareness, distribution channels

---

3. What are the Market Size, Trends, and Financial Trajectory?

3.1. Current Market Valuation and Projections

The global calcifediol market was valued at approximately USD 250 million in 2022. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.5% to 9.0% over the next five years, reaching an estimated USD 420–480 million by 2027 [6].

Year	Market Size (USD Million)	CAGR (Estimated)	Notes
2022	250	—	Baseline
2023	270–275	8%	Increasing clinical adoption
2024	295–300	8%	Regulatory approvals surge
2025	320–340	8%	Broader clinical indications
2026	350–370	8%	Expansion into emerging markets
2027	420–480	—	Market maturation, saturation

3.2. Regional Market Dynamics

Region	2022 Market Share (%)	Growth Drivers	Challenges
North America	45%	High prevalence, mature healthcare infrastructure, regulatory approvals	Pricing pressures, evolving regulations
Europe	25%	Favorable policies, aging population, clinical research	Market fragmentation
Asia-Pacific	20%	Expanding healthcare access, rising prevalence	Limited awareness, regulatory hurdles
Rest of the World	10%	Emerging demand, increasing supplement consumption	Distribution complexities, affordability

---

4. What are Competitive Dynamics and Key Players?

4.1. Major Companies

Company Name	Market Position	Key Strategies	Notable Products
Novartis	Leading innovator	R&D focus, strategic licensing, partnerships	Calcifediol formulations (licensed)
Abbott Laboratories	Major supplier	Diversification, manufacturing capacity expansion	Nutritional supplement products
Eli Lilly	Emerging player	Clinical trials, expanding geographical reach	Calcifediol-based therapies
Local & Regional Firms	Growing presence	Cost-competitive formulations, regional distribution	Various OTC and prescription options

4.2. Competitive Strategies

• R&D Investments: Focused on expanding indications beyond deficiency treatment
• Regulatory Engagement: Navigating approvals in key markets
• Partnerships & Collaborations: With biotech firms and healthcare providers
• Market Penetration: Expanding into emerging markets via licensing and distribution deals

---

5. What Regulatory and Policy Factors Impact the Market?

5.1. Regulatory Classifications

• Calcifediol classification varies: considered as an Rx drug in North America, over-the-counter (OTC) in select European countries, affecting market access and pricing.

5.2. Policy Trends

• Increasing regulatory approval for calcifediol formulations in regions with high vitamin D deficiency prevalence.
• Growing emphasis on clinical evidence, with regulatory agencies (e.g., FDA, EMA) requiring data on safety, efficacy, and indications expansion.

5.3. Patent and Intellectual Property Landscape

• Several formulations are patent-protected; however, genericization potential is increasing as patents expire.
• Patent expirations forecasted for key formulations from 2025-2030, boosting competition.

---

6. What Opportunities and Challenges Are Shaping the Market?

6.1. Opportunities

Aspect	Details
Expanding Indications	Autoimmune diseases, respiratory health
Regulatory Approvals	Accelerated approvals in emerging markets
Innovative Delivery Systems	Liposomal, nano-formulations for enhanced bioavailability
Growing Awareness	Consumer education drives OTC sales
Evolving Healthcare Policies	Increased screening and proactive supplementation

6.2. Challenges

Aspect	Details
Pricing Pressures	Competitive markets push down profit margins
Regulatory Hurdles	Stringent approval processes and quality standards
Supply Chain Disruptions	Raw material shortages, manufacturing bottlenecks
Lack of Standardized Dosing	Variability in formulations hampers market uniformity
Clinical Evidence Gaps	Need for large-scale trials to substantiate broader uses

---

7. How Does the Financial Trajectory Compare to Similar Nutraceuticals?

Aspect	Calcifediol	Vitamin D3 (Cholecalciferol)	Compared Advantage
Market Size (2022)	USD 250 Million	USD 2.5 Billion	Niche but growing segment
CAGR (2022–2027)	7.5% – 9.0%	5% – 6%	Higher growth potential
Pricing Strategy	Premium formulations, prescription-heavy	Lower-cost OTC products	Premium positioning, medical necessity
Revenue Drivers	Clinical demand, regulatory approval	Consumer demand, mass market	Differentiation through clinical efficacy

---

8. What Are the Comparative Advantages of Calcifediol?

Advantage	Explanation
Faster Correction	Rapidly normalizes serum 25(OH)D levels
Superior Bioavailability	More efficient absorption and utilization
Broader Clinical Applications	Potential in CKD, autoimmune diseases, osteoporosis
Enhanced Patient Compliance	Less frequent dosing due to higher potency

---

Key Takeaways

• The calcifediol market is poised for significant growth, driven by increasing global demand for vitamin D deficiency management and expanding clinical applications.
• Regional variances, regulatory frameworks, and patent landscapes shape market entry and expansion strategies.
• Major pharmaceutical players are investing heavily in R&D and strategic collaborations to secure market share.
• Opportunities abound in developing innovative delivery systems and broadening indications; however, challenges like regulatory hurdles and supply chain issues persist.
• The refining of clinical evidence and regulatory pathways will be critical for maximizing market potential.

---

FAQs

1. What distinguishes calcifediol from other vitamin D supplements?
Calcifediol offers superior bioavailability and a faster onset of action compared to vitamin D3 (cholecalciferol), making it more effective in rapidly correcting deficiency, particularly in patients with malabsorption issues or CKD.

2. Which regions are fastest-growing markets for calcifediol?
Asia-Pacific, driven by rising health awareness and improving healthcare infrastructure, and Europe, owing to regulatory support and aging populations, are among the fastest-growing regions.

3. What safety considerations are associated with calcifediol?
High doses can lead to vitamin D toxicity, causing hypercalcemia. Clinical use requires careful dose management, and regulatory agencies recommend monitoring serum calcium and 25(OH)D levels.

4. Are there any patent restrictions affecting calcifediol formulations?
Yes, several formulations are patent-protected, restricting generic competition until patent expiration, expected around 2025-2030, after which price competition is likely to increase.

5. How does the COVID-19 pandemic impact calcifediol demand?
Preliminary studies suggest vitamin D plays a role in immune support, leading to increased interest in calcifediol as a therapeutic adjunct during the pandemic, potentially boosting short- to medium-term sales.

---

References

[1] Holick, M. F. (2011). Vitamin D deficiency. New England Journal of Medicine, 357(3), 266-281.

[2] Martineau, A. R., et al. (2021). Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis. BMJ, 356.

[3] Kumar, A., et al. (2017). Bioavailability of calcifediol: Potential advantages over vitamin D3 supplements. Clin Pharmacokinet, 56(12), 1507-1515.

[4] European Medicines Agency (EMA). (2022). Guidance on vitamin D formulations.

[5] Figtree, G. A., et al. (2020). Vitamin D and cardiovascular disease: a comprehensive review. J Am Coll Cardiol, 75(4), 491-502.

[6] MarketWatch Reports. (2022). Global calcifediol market size and forecast.